Chronic Lymphocytic Leukemia (CLL) Research & Clinical Trials
Discover the latest research advances and clinical trials for chronic lymphocytic leukemia (CLL). Explore targeted therapies, precision medicine approaches, treatment optimization studies, and novel treatment combinations transforming CLL care and improving patient outcomes.
Understanding Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, affecting approximately 20,000 Americans annually. CLL is typically a slow-growing cancer of B-lymphocytes, though it can become more aggressive over time.
CLL treatment has been revolutionized by targeted therapies that are highly effective and often taken as oral medications. Many patients achieve durable responses with excellent quality of life. Research continues to optimize treatment approaches and identify patients who can safely achieve treatment-free remission.
Treatment Evolution
CLL treatment has evolved from primarily chemotherapy-based approaches to targeted therapies that are more effective and better tolerated. Research now focuses on optimizing combinations, sequencing strategies, and identifying who can safely stop treatment after achieving deep remission.
Active CLL Research Projects
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Principal Investigator: Dr. William G Wierda
Institution: City of Hope Comprehensive Cancer Center
Location
Duarte, California
Timeline
Start: January 2021
Completion: December 2024
Modern CLL Treatment Approaches
Targeted Therapies
BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax) are highly effective oral medications that target specific molecular pathways in CLL cells. These drugs have transformed CLL treatment, achieving high response rates with manageable side effects.
Combination Strategies
Research explores combining targeted drugs for deeper responses and potentially allowing treatment-free intervals. Fixed-duration combination therapy is showing promise in achieving undetectable minimal residual disease.
Treatment-Free Remission
Some patients achieve deep remission allowing treatment to be stopped while maintaining disease control. Research identifies which patients can safely achieve treatment-free periods, improving quality of life while maintaining outcomes.